University of Colorado Hospital Policy and Procedure:
Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients
Related Policies and Procedures: Neutropenic Management for Oncology and Hematopoietic Stem Cell Transplant Patients Standard Precautions Autologous and Allogeneic Bone Marrow Re-infusion, Peripheral Progenitor and Double Cord Cell Re-infusion Hand Hygiene-Outside the Surgical Setting Infection Control Surveillance Isolation/Transmission Based Precautions Blood/Body Fluid Spills Aseptic Technique in Invasive and Operative Procedures Clean/Sterile Supply Storage in Clinical Areas Infectious/Regulated Waste Management Employee Work Restrictions for Infectious Diseases Live Plant and Flower Restrictions Diet Restrictions and Recommendations for the Hematology and Oncology Central Venous Lines Animal Assisted Activities/Therapy Program
Approved by: Professional Practice, Policy, and Procedure Committee Effective: 06/14
Description: This policy defines neutropenia, as well as febrile neutropenia, and the necessary assessment parameters, guidelines, interventions, and environmental modification that must be implemented by University of Colorado Hospital (UCH) health care providers in UCH clinical settings when caring for neutropenic/immunocompromised Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT) Patients.
Accountability: All University of Colorado Hospital employees, physicians, volunteers, students, temporary and contract employees are responsible for complying with the precautions/measures described in this policy.
Definitions: Hematological Malignancies: Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer. (National Cancer Institute)
Neutrophils are the bodys first line of defense against microbial invasion. They constitute approximately 40%-60% of the total white blood cell count that usually ranges from 4,000- Wenger, Barbara 5/23/14 9:36 AM Wenger, Barbara 5/23/14 9:56 AM Formatted: Font:12 pt, Not Bold Wenger, Barbara 5/23/14 9:56 AM Formatted: Font:12 pt, Not Bold Wenger, Barbara 5/23/14 9:37 AM Wenger, Barbara 5/23/14 9:37 AM Wenger, Barbara 5/23/14 9:38 AM Wenger, Barbara 5/23/14 9:45 AM Wenger, Barbara 5/23/14 9:42 AM Deleted: University of Colorado Hospital Nursing Practice Guideline Bone Marrow Transplant Unit: Deleted: Director Hematologic Malignancies and BMT Programs Oncology/Bone Marrow Transplant Clinical Nurse Specialist Bone Marrow Transplant/Cancer Center Practice Manager Effective: 5/14 Deleted: guideline Deleted: Deleted: guideline Deleted: Visitors and other non-hospital-employee personnel will be informed of and asked to comply with the provisions of this guideline by the University of Colorado Hospital staff. Non- compliance will be dealt with on an individual basis. Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 2 of 10
Wenger, Barbara 5/23/14 10:12 AM 10,000/mm 3 .
Neutropenia is defined as an absolute neutrophil count (ANC) less than 500/mm 3
1. The relative risk for infection increases as the ANC decreases. The ANC is categorized into grades, which reflect the risk for infection. a. Grade 1: ANC 1500-2000/mm 3 = No Significant Risk b. Grade 2: ANC 1000-1500/mm 3 =Slight Increase in Risk c. Grade 3: ANC 500-1000/mm 3 =Moderate Risk d. Grade 4: ANC less than 500/mm 3 =High Risk=Neutropenia for BMT population.
Signs and Symptoms of Infection 1. Localized symptoms of infection: pain at the site of infection that may or may not include erythema or exudate. 2. Generalized symptoms of infection: chills, myalgias, arthralgias, cognitive or mental status changes, anorexia, nausea/vomiting, fatigue, tachycardia, hypotension, tachypnea, hypoxemia, oliguria, and fever. 3. Site-Specific symptomatology/exam findings: cough, dyspnea, abnormal breath sounds oral pain, back pain, rigors, rectal discomfort with bowel elimination, pain at vascular access device site, burning/urgency with urination.
Sources of Infection 1. The skin and mucous membranes are vulnerable sources of microbial invasion due to IV/Central line access and mucositis. Additional risk factors include GVHD (Graft versus Host Disease), and toxicities from conditioning regimens that cause prolonged neutropenia (10-30 days). 2. Primary sites of infection in the neutropenic patient are the digestive tract (mouth, pharynx, esophagus, large and small bowel, rectum), as well as the sinuses, lungs, and skin. 3. Hand hygiene is considered the most important procedure to prevent the spread of infections. Refer UCH Policy and Procedure: Hand Hygiene-Outside The Surgical Setting. Table of Contents: (Required on any Policy/Procedure longer than 5 pages. Will auto update if using this as a template.) I. Subtitle 1 II. Subtitle 2 2 A. Procedural Step 2 B. Procedural Step 2 C. Procedural Step 2 III. Subtitle 3 2 A. Procedural Step 2 B. Procedural Step 2 C. Procedural Step 2 D. Procedural Step 2 IV. Subtitle 4 2 V. Subtitle 5 2 Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Wenger, Barbara 5/23/14 9:46 AM Deleted: =Neutropenia Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 3 of 10
Wenger, Barbara 5/23/14 10:12 AM A. Procedural Step 2 B. Procedural Step 2 References 3
Policies and Procedures: I. Assessment Parameters A. Fever (single temperature greater than or equal to 38.3 degrees Celsius or a temperature greater than or equal to 38 degrees Celsius sustained for greater than one hour) is usually the first and only sign of a potentially life-threatening infection. B. Localized symptoms of infection such as redness, swelling, pain, and exudate may not be present due to the inability of the patients body to create an inflammatory response resulting from the absence or decreased number of neutrophils.
C. Although uncommon, a patient with neutropenia and signs or symptoms of infection (i.e. abdominal pain, severe mucositis, or perirectal pain) without fever, should be considered to have an active infection.
II. Assessment Guidelines A. Determine expected duration and severity of neutropenia 1. Consider the patients current and past treatment regimens including one or more of the following: chemotherapy, radiation therapy, immunotherapy, immunosuppressive therapy, HSCT. 2. Consider the patients comorbitities, medications, history of prior documented infections, recent antibiotic therapy, exposure to infections from household members, pets, travel (including Tuberculosis exposure), HIV status, and recent blood product administration. B. Assess for common sites of infection in patients with fever and neutropenia: the alimentary tract, groin, skin, lungs, sinus, ears, perivagina, perirectum, and vascular access device sites C. Monitor vital signs Q4h or more often depending on clinical situation (Provider decision) D. Monitor Intake and Output Q4h E. Obtain BID weights on all active HSCT patients and all HSCT that are readmitted post transplant. F. Monitor laboratory data: 1. CBC with differential, including WBC count. If ANC less than 1000, institute neutropenic precautions. Refer to Neutropenic Precautions sign (Appendix A). 2. Comprehensive Metabolic Panel, LDH, Uric Acid, Creatinine, BUN, LFTs, Total Serum Bilirubin, and lactate as ordered by provider. 3. Blood and other Culture Reports-notify Provider if positive and institute appropriate transmission based precautions if necessary. Refer to UCH Policy and Procedure: Isolation/Transmission Based Precautions. Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Wenger, Barbara 5/23/14 9:40 AM Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Wenger, Barbara 5/23/14 9:57 AM Deleted: Practice Guidelines: Deleted: (T,P,R,BP) Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 4 of 10
Wenger, Barbara 5/23/14 10:12 AM 4. Consult Provider for potential chest x-ray, urinalysis, urine culture/sensitivity, and pulse ox. Chest x-ray for all patients with respiratory symptoms.
III. Nursing Intervention For Treatment of Febrile Neutropenia 1. Febrile Neutropenia/Immunocompromised Fever in Hematologic Malignancies and HSCT 1. Patients admitted for HSCT are treated with prophylactic antibiotics prior to becoming neutropenic and throughout the expected neutropenic state during hospitalization. Once patients receive their stem cells, they may begin Hematopoietic Growth Factors (Dual cord SCT or Autologous SCT) therapy to assist in WBC recovery. Refer to EHR for details. 2. When a patient becomes febrile (a single temperature greater than or equal to 38.3 degrees Celsius or temperature greater than or equal to 38 degrees Celsius sustained for greater than one hour), refer to EHR , which indicate obtaining a chest x-ray, urinalysis, urine culture and sensitivity, and at least two sets of blood cultures. At least one of the two sets of cultures is to be obtained from the patients vascular access device if present. a. Collaborate with the Provider regarding obtaining one of the two sets of blood cultures peripherally. 3. According to the 2013 NCCN guidelines, if there is entry or exit site inflammation around the vascular access device; 1) obtain a set of blood cultures from each lumen 2) swab exit site drainage (if present) for culture and 3)Vancomycin should be considered. If the vascular access device cultures are positive for infection, collaborate with the Provider regarding obtaining further blood cultures from each lumen, removal of vascular access device, and additional antibiotic therapy. Notify provider immediately if port pocket infection is suspected. Do not access the implanted port if infection is suspected due to increased risk of further infection. 4. If patient symptomatology warrants, collaborate with the Provider regarding obtaining site-specific cultures including rectal, stool, skin, mouth, throat, sputum, and nasopharynx. 5. If patient continues to be febrile, blood cultures are to be done once every 24 hours. Other diagnostic tests such as, chest x-ray, urinalysis, urine culture and sensitivity, ect. may be ordered based on provider preference. 6. Refer to EHR for fever day antibiotic instructions. Once the patient is febrile (a single temperature greater than or equal to 38.3 degrees Celsius or temperature greater than or equal to 38 degrees Celsius sustained for greater than one hour ), antibiotics are to be given according to Fever Day 1 instructions. Initiate antibiotic therapy within the hour of the fever but not before obtaining blood cultures. DO NOT HOLD ANTIBIOTICS FOR COMPLETION OF CHEST X-RAY AND/OR URINE TESTS. For each subsequent fever not within consecutive 24-hour periods, collaborate with Provider regarding antibiotics to start/discontinue. If a patient continues to be febrile for consecutive 24-hour periods, continue to follow the EHR indicating which antibiotics to administer. Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Wenger, Barbara 5/23/14 9:58 AM Wenger, Barbara 5/23/14 9:58 AM Deleted: G-CSF Deleted: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 5 of 10
Wenger, Barbara 5/23/14 10:12 AM 7. S/P Hematopoietic Stem Cell Transplant Patients returning to the hospital for complications related to their transplant, including infection, are to be directly admitted to the Hematopoietic Stem Cell Transplant unit when possible. When a bed is not available, consult with provider regarding appropriate triage. a. If patient is febrile, ED Provider is to collaborate with Heme/BMT Provider regarding ED Approach to Patient with Possible Neutropenic Fever (Appendix B). Heme/BMT Pager: 303-266-4162 b. If patient is being admitted through the ED or Inpatient due to a fever refer to the BMT/HEME ED/INPATIENT RAPID RESPONSE FEVER PROTOCOL (RRFP) (Appendix C)
B. Environmental Modification 1. All neutropenic patients are placed in private rooms. Patients admitted for HSCT are to be placed in positive pressure rooms with HEPA filtration. 2. Neutropenia precaution sign is to be placed beside the door to alert staff and visitors of infection prevention protocol/measures. Refer to Neutropenic Precautions sign (Appendix A).
C. Protective Measures for Neutropenic Patients 1. Handwashing is the single most important intervention to prevent infection. Refer to policy for: Hand Hygiene-Outside the Surgical Setting. 2. Anyone with symptoms of illness is to avoid contact with neutropenic patients. When contact is unavoidable, staff/visitors are to wear masks when entering the patients room and adhere to proper hand hygiene. 3. Children under the age of 12 are not to enter the Hematopoietic Stem Cell Transplant unit regardless of the presence of neutropenic patients. 4. Once neutropenic, ANC less than 500, these patients are to be instructed to wear this mask whenever they leave their room. 5. HSCT patients in contact isolation refer to policy: Isolation/Transmission Based Precautions. 6. Avoid rectal maneuvers (rectal temperatures, enemas, rectal medications, rectal tubes, digital exams) and urinary catheterizations. 7. Avoid breakdown of skin and mucous membranes by limiting venipunctures or other invasive procedures. Cleanse and protect wounds that break the skin as directed by the Provider. 8. Diet restrictions- Refer to policy: Diet Restrictions and Recommendations for the Hematology and Oncology Immunocompromised Patient 9. Change urinals and hats when visibly soiled. Change nasal cannulas, O2 masks weekly and when visibly soiled. 10. Encourage consistent patient personal hygiene a. Daily shower or bath, including shampooing head/hair. Use CHG wipes as directed for central line care. b. Change linens daily and more frequently if visibly soiled. c. Routine oral care. Recommended to brush teeth with a soft toothbrush four times daily and then rinse with salt and soda mixture after each Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Wenger, Barbara 5/23/14 10:07 AM Formatted: Left, Tabs:Not at 1" Wenger, Barbara 5/23/14 10:07 AM Wenger, Barbara 5/23/14 10:07 AM Formatted: Font:Italic Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Wenger, Barbara 5/23/14 10:01 AM Wenger, Barbara 5/23/14 10:02 AM Wenger, Barbara 5/23/14 10:02 AM Wenger, Barbara 5/23/14 10:06 AM Formatted: Font:Italic Wenger, Barbara 5/23/14 10:06 AM Formatted: Font:Italic Wenger, Barbara 5/23/14 10:04 AM Wenger, Barbara 5/23/14 10:06 AM Formatted: Font:Italic Wenger, Barbara 5/23/14 10:05 AM Deleted: All persons entering the room will soap and wash hands at time of entry and time of exit with either alcohol based gel or with soap and water for 15 seconds Deleted: 1000 Deleted: who are under Deleted: due to their being infected with a highly transmissible infectious organism, such as VRE and MRSA, are to remain in their room at all times, unless required to leave their room for testing. In this case, the patient is to wear appropriate PPE, including yellow gown, and gloves. If the patient is neutropenic and/or under airborne/droplet precautions a mask is to be worn Deleted: the Deleted: (provided by nursing staff) Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 6 of 10
Wenger, Barbara 5/23/14 10:12 AM brushing. If patient not on the 11 th ,floor unit, contact BMT unit to acquire supplies. 11. Live plant and flowers are not allowed in the rooms of neutropenic patients whose immune compromise is such that infection can be acquired from soil/plant organisms. Refer to UCH Policy and Procedure: Live Plant and Fresh Flower Restrictions. 12. Animals are restricted from the HSCT unit due to the potential infection risk for the immunocompromised patient population. Refer to UCH Policy and Procedure: Animal Assisted Activities/Therapy Program.
References: 1. Dellinger R.P., Levy M.M., Rhodes A, et al. (2012) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine. 41(2):580-637. (LOE 7) 2. Irwin, M., Erb, C., Williams, C., Wilson, B., & Zitella, L. (2013). Putting Evidence Into Practice:Improving Oncology Patient Outcomes. Pittsburgh, PA: Oncology Nursing Society. (LOE 1) 3. Marrs, J. (2006). Care of Patients With Neutropenia. Clinical Journal of Oncology Nursing, 10(2), 164-166. (LOE 8) 4. National Cancer Institute: NCI Dictionary of Cancer Terms. Retrieved from: http://www.cancer.gov/dictionary?CdrID=45708 (LOE 8). 5. NCCN. (2013). Fever and Neutropenia-v.1.2013. NCCN Clinical Practice Guidelines in Oncology. (CD). Jenkintown, PA: NCCN. (LOE 7) 6. Nirenberg, A., Bush, A.P., Davis, A., Friese, C.R., Gillespie, T.W., Rice, R.D. (2006). Neutropenia: State of the Knowledge Part I/Part II. Clinical Journal of Oncology Nursing, 33(6), 1193-1201, 1202-1208. (LOE 8) 7. Shelton, B.K. (2003). Evidence-Based Care for the Neutropenic Patient with Leukemia. Seminars in Oncology Nursing, 19(2), 133-141. (LOE 7) 8. Zitella, L., Friese, C., Hauser, J., Holmes, B.G., Woolery, M.A., OLeary, C., Andrews, F. (2006). Putting Evidence Into Practice: Preventions of Infection. Clinical Journal of Oncology Nursing, 10(6), 739-750. (LOE 1)
Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Wenger, Barbara 5/23/14 10:05 AM Formatted: Superscript Pamela Heinke 5/13/14 3:57 PM Formatted: Bullets and Numbering Wenger, Barbara 5/23/14 10:09 AM Deleted: 1 Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 7 of 10
Visitors with cold symptoms or contagious illness should not visit patient at this time. Patient MUST wear a mask when leaving room.
NO FRESH FLOWERS OR PLANTS.
DIETARY RESTRICTIONS INCLUDE:
Fresh fruit and vegetables ONLY if washed under running water prior to peeling, cutting, or eating (berries and sprouts excluded) NO soft cheeses, unpasteurized foods/fluids, or pepper (from pepper shakers or pepper mills) NO undercooked or raw meat, fish, eggs, or tofu. Unroasted nuts or nuts in a shell Teas will be prepared directly by staff for patient by request.
PLEASE SEE THE NURSE IF YOU HAVE ANY QUESTIONS REGARDING THESE PRECAUTIONS
(OTR09029-0911 DOD)
Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Wenger, Barbara 5/23/14 10:13 AM Deleted: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 8 of 10
Wenger, Barbara 5/23/14 10:12 AM Appendix B
ED Approach to Immunocompromised Patients and/or Possible Neutropenic Fever
ED GOAL: PLEASE PAGE THE BMT/HEME TEAM IMMEDIATELY UPON PATIENT TRIAGE Pager: 303-266-4162 ! To administer antibiotics within 1 hour of ED presentation for Immunocompromised/Neutropenic Patients
PIVOT PROCEDURE: ! Identify high risk patient at Pivot Patient s/p chemotherapy/radiation treatment within 14 days Patient s/p hematopoietic stem cell transplant Hematologic Malignancies with fevers or other vague complaints ! Provide and instruct suspected neutropenic patient to wear a mask ! Obtain patients weight ! Document Neutropenic Patient in comments on tracking board ! Assign patient to an Intake room from pivot (single patient area) to be evaluated by an attending physician. Intake attending may include neutropenic precautions if the patient has known or suspected neutropenia. The patient may then be placed in an ED treatment room in Main ED if recommended by provider. ! Notify Resource Nurse, who will notify attending or senior resident of patients arrival. Call HEME/BMT Pager 303-266-4162 upon patient arrival to the Emergency Department. ! Place Neutropenic packet of algorithms on patients chart and verify allergies once patient is in the Main ED.
ED PROCEDURE: INITIATE RAPID RESPONSE FEVER PROTOCOL (RRFP) BASED ON ED OR HEME/BMT PROVIDER ORDER ENTRY. FOLLOW APPENDIX C.
Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Wenger, Barbara 5/23/14 10:11 AM Deleted: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 9 of 10
Wenger, Barbara 5/23/14 10:12 AM Appendix C BMT/ HEME ED/ INPATIENT RAPID RESPONSE FEVER PROTOCOL (RRFP) Patient Qualifies for RAPID RESPONSE FEVER PROTOCOL Hospital Admission Please note: This pathway is NOT an order set. This is a guideline for MDs/RNs for the INITIAL (first hour) management of Heme/BMT patients who present to the ED or Inpatient Unit with FEVER or other signs of serious infection. This pathway will be accompanied by an order set. PLEASE PAGE THE BMT/ HEME TEAM IMMEDIATELY UPON PATIENT TRIAGE Pager: 303-266-4162 " Vital Signs Every 15min. X4, then every 30min. X2, then every 60min. " Labs (CBC/diff, CMP, Mg, Phos, LDH, Uric acid, Lactate) " Blood cultures (2 sets from Central Line and 1 simultaneous peripheral set) If difficult peripheral stick, complete Central Line cultures only OR 2 set peripherally if no Central Line " IV Fluid Bolus (NS 1000cc wide open) If patient unstable (SBP<90, HR>120, dizziness, altered mental status), start IV Fluid Bolus immediately after Vital Signs and notify NP/MD immediately " ANTIBIOTICS (Please use the RRFP FEVER order set) cefepime 2gm IV Q8 +/- Vancomycin (use ONLY if hemodynamic instability, suspected line or skin infection, suspected MRSA, PNA, mucositis) If severe allergy to PCN/cephalosporins, use alternative antibiotics per RRFP order set Above interventions to be completed within 30 min. of patient #########arrival to ED/Inpatient Unit if Direct Admit########## " Diagnostic Testing/Source ID CXR, CT, UA C&S, etc. Do NOT delay antibiotics waiting for CXR or UA!! " 11 th Floor Inpatient Management OR ICU Transfer for EGDT if Unstable Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:15 AM Formatted Table Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:15 AM Formatted Wenger, Barbara 5/23/14 10:15 AM Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Wenger, Barbara 5/23/14 10:14 AM Formatted Deleted: ... [1] ... [2] ... [3] ... [4] ... [5] ... [6] ... [7] ... [8] ... [9] ... [10] ... [11] ... [12] ... [13] ... [14] ... [15] ... [16] ... [17] ... [18] ... [19] ... [20] ... [21] ... [22] ... [23] ... [24] ... [25] ... [26] ... [27] ... [28] ... [29] ... [30] ... [31] ... [32] Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Page 10 of 10
Wenger, Barbara 5/23/14 10:12 AM
Deleted: Bone Marrow Transplant Unit: Neutropenic/Immunocompromised Management for Hematologic Malignancies and Hematopoietic Stem Cell Transplant Patients Wenger, Barbara 5/23/14 10:15 AM Deleted: